PDGFRβ Ligand

Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.

pPB peptide is a cyclic peptide targeting platelet-derived growth factor receptor β (PDGFRβ). Derived from natural platelet-derived growth factor (PDGF), pPB peptide contains arginine and isoleucine as key receptor-binding residues. pPB peptide specifically binds to PDGFRβ, which is highly expressed on the surface of activated hepatic stellate cells (HSC). pPB peptide can be used in studies related to liver fibrosis, liver cirrhosis, and tumor-specific drug delivery.